Silo pharma secures biomarker patent for novel ptsd therapeutic spc-15 as clinical trial nears

Sarasota, fl, june 11, 2025 (globe newswire) -- silo pharma, inc. (nasdaq: silo) (“silo” or the “company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that the u.s. patent and trademark office (uspto) had issued a notice of allowance for u.s. patent application no. 17/954,858 (titled “biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders”) that silo licenses from columbia university.
SILO Ratings Summary
SILO Quant Ranking